Khanna R - Search Results

1

Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.

Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group. Vermeire S, et al. Among authors: khanna r. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798037 Clinical Trial.

2

Through the looking glass: a journey toward optimal endoscopic assessment of disease activity in ulcerative colitis.

Khanna R, Feagan BG. Khanna R, et al. Clin Gastroenterol Hepatol. 2013 Jan;11(1):55-6. doi: 10.1016/j.cgh.2012.09.024. Epub 2012 Sep 27. Clin Gastroenterol Hepatol. 2013. PMID: 23022700 No abstract available.

3

Ustekinumab for the treatment of Crohn's disease.

Khanna R, Feagan BG. Khanna R, et al. Immunotherapy. 2013 Aug;5(8):803-15. doi: 10.2217/imt.13.81. Immunotherapy. 2013. PMID: 23902548 Review.

4

Challenging question: is treating inflammatory bowel disease an art or strictly an evidence-based matter?

Khanna R, Mosli MH, Feagan BG. Khanna R, et al. Dig Dis. 2013;31(2):213-7. doi: 10.1159/000353371. Epub 2013 Sep 6. Dig Dis. 2013. PMID: 24030228 Review.

5

Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD.

Khanna R, Feagan BG. Khanna R, et al. Curr Treat Options Gastroenterol. 2014 Mar;12(1):76-89. doi: 10.1007/s11938-013-0005-4. Curr Treat Options Gastroenterol. 2014. PMID: 24395613

6

Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.

Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, Levesque BG. Vande Casteele N, et al. Among authors: khanna r. Curr Gastroenterol Rep. 2014 Apr;16(4):378. doi: 10.1007/s11894-014-0378-0. Curr Gastroenterol Rep. 2014. PMID: 24595615 Free article. Review.

7

Toward a personalized medicine approach to the management of inflammatory bowel disease.

Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Mosli MH, et al. Among authors: khanna r. Am J Gastroenterol. 2014 Jul;109(7):994-1004. doi: 10.1038/ajg.2014.110. Epub 2014 May 20. Am J Gastroenterol. 2014. PMID: 24842338 Review.

8

A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.

Khanna R, Bouguen G, Feagan BG, DʼHaens G, Sandborn WJ, Dubcenco E, Baker KA, Levesque BG. Khanna R, et al. Inflamm Bowel Dis. 2014 Oct;20(10):1850-61. doi: 10.1097/MIB.0000000000000131. Inflamm Bowel Dis. 2014. PMID: 25029615 Review.

9

Vedolizumab for induction and maintenance of remission in ulcerative colitis.

Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, MacDonald JK, Khanna R, Feagan BG. Bickston SJ, et al. Among authors: khanna r. Cochrane Database Syst Rev. 2014 Aug 8;(8):CD007571. doi: 10.1002/14651858.CD007571.pub2. Cochrane Database Syst Rev. 2014. PMID: 25105240 Review.

10

Assessment of histologic disease activity in Crohn's disease: a systematic review.

Mojtahed A, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Shackelton LM, Baker KA, Dubcenco E, Valasek MA, Geboes K, Levesque BG. Mojtahed A, et al. Among authors: khanna r. Inflamm Bowel Dis. 2014 Nov;20(11):2092-103. doi: 10.1097/MIB.0000000000000155. Inflamm Bowel Dis. 2014. PMID: 25137418 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,041 results

Search Page